instruction:
In this task, you are given a summary for US Congressional and California state bill, your task is to generate a Title for this bill. The preferred titles are under forty words and mention the purpose of the bill.
question:
Ricky Ray Hemophilia Relief Fund Act of 1995 - Establishes in the U.S. Treasury the Ricky Ray Hemophilia Relief Fund.  Authorizes appropriations. 
Specifies that any individual who submits to the Attorney General written medical documentation that the individual has a human immunodeficiency virus (HIV) infection shall receive $125,000 from amounts available in the Fund if the individual:  (1) has a blood-clotting disorder and was treated with blood-clotting agents between January 1, 1980, and December 31, 1987; (2) is the lawful spouse of such individual or the former lawful spouse and was the lawful spouse of the individual at any time after a date within such period on which the individual was treated; or (3) acquired the HIV infection through perinatal transmission from a parent who is such an individual. Requires that a claim for payment be filed with the Attorney General by or on behalf of such individual and that the Attorney General determine that the claim meets the requirements of this Act. 
Specifies that a claim under this Act shall not be assignable or transferable.  Sets limits regarding the number of claims per victim. Prohibits the Attorney General from paying claims filed under this Act unless filed within three years after this Act's enactment.
answer:
Ricky Ray Hemophilia Relief Fund Act of 1995


question:
Department of State Authorities Act, Fiscal Year 2017, Improvements Act This bill makes technical changes to the Department of State Authorities Act, Fiscal Year 2017 and other related Acts. The bill provides the House and Senate Appropriations Committees with oversight authority regarding congressional reports on: (1) high-risk diplomatic and consular posts, (2) embassy construction costs, (3) combating sexual exploitation in United Nations (U.N.) peacekeeping operations, (4) Department of State overseas staffing levels, and (5) reducing illicit drug supply and abuse in the Western Hemisphere.  The bill provides such committees with oversight authority regarding the granting of consular immunity. The Department of State Authorities Act, Fiscal Year 2017 is amended regarding: (1) replacement of a specified reference to anti-Semitism with a reference to intolerance; (2) the definition of &quot;change to the federal status&quot; with respect to the Cuba Service and the Television Marti Service; (3) the report on the costs, strengths, and limitations of U.S. and U.N. peacekeeping operations; (4) U.N. peacekeeper training to reduce sexual exploitation; (5) the U.N. Secretary General; (6) Foreign Service entry; (7) completion of the Western Hemisphere Drug Policy Commission report; and (8) ransoms to foreign terrorist organizations. The United States should use its influence to prohibit U.N. Human Rights Council membership to a country: (1) designated as a Tier 3 human trafficking country, or (2) identified as having failed to prevent or address gross violations of human rights.   The President shall report to Congress regarding steps taken to encourage China to enter into a dialogue with the Dalai Lama leading to a negotiated agreement on Tibet. 
answer:
Department of State Authorities Act, Fiscal Year 2017, Improvements Act


question:
Amends the Federal Food, Drug, and Cosmetic Act to require license applications for new drugs and biological products to assess such drug's or product's safety and effectiveness for relevant pediatric subpopulations, including dosage.Permits extrapolation from adult studies where the course of the disease and the effects of the drug are sufficiently similar in all populations.Permits deferral of such assessments if adult studies are completed earlier and the applicant submits a plan for or a description of planned or ongoing pediatric studies.Permits full waiver of such assessments if: (1) studies are highly impractical or impossible; (2) the evidence strongly suggests that the drug or product would be ineffective or unsafe in all pediatric age groups; (3) there is no meaningful therapeutic advantage or benefit in the pediatric population; or (4) the drug or product is not likely to be used in a substantial number of pediatric patients.Permits partial waivers at the request of an applicant for a specific pediatric subpopulation if any of the full waiver grounds apply to that subpopulation or reasonable attempts for a pediatric formulation for that subpopulation have failed.Requires labels to provide indication in cases in which a waiver has been granted due to evidence a product would be unsafe or ineffective in pediatric populations.Authorizes the Secretary of Health and Human Services to specify a date for submission of pediatric assessments if: (1) the drug or biological product would represent a meaningful therapeutic benefit for pediatric patients for one or more claimed indications and the absence of adequate labeling could pose significant risks to pediatric patients; or (2) it is used for a number of pediatric patients for the labeled indications and the absence of adequate labeling could pose significant risks to pediatric patients. Sets forth criteria for full waiver and partial waivers of such requirement. Requires labels to provide indication in cases in which a waiver has been granted due to evidence a product would be unsafe or ineffective in pediatric populations.Requires the Secretary to issue a written request for related pediatric studies under the Public Health Service Act before requiring an assessment for a drug.States that drugs or products with delayed assessments may be deemed misbranded and subject to seizure and injunctive proceedings, though not penalties.
answer:

To amend the Federal Food, Drug, and Cosmetic Act to require labeling containing information applicable to pediatric patients.